Sep 2026· Journal of Chemical Information and Modeling· 0 citations· 65 references
TL;DR
This study establishes C367 as a druggable covalent site in the historically challenging STAT3 DBD, validates FEP-guided optimization of covalent inhibitors, and identifies compound 16 as a promising next-generation lead with a superior drug-like profile for targeting STAT3-dependent cancers.
Abstract
Pancreatic cancer remains a highly lethal malignancy, largely due to persistent STAT3 signaling that sustains cancer stem cells (CSCs) and drives therapeutic resistance. Conventional inhibitors targeting the conserved SH2 domain of STAT3 have exhibited limited selectivity and efficacy. Here, we report that micheliolide (MCL), the active metabolite of the clinical-stage candidate ACT001, inhibits STAT3 through Cys367 (C367)-dependent covalent engagement within the DNA-binding domain (DBD)–a residue unique to STAT3 among STAT family members. This specific modification disrupts STAT3 phosphorylation at Tyr705, nuclear translocation, and transcriptional activity prior to any detectable inhibition of upstream JAK phosphorylation, a finding that suggests that STAT3 inhibition is not primarily driven by upstream kinase blockade. Guided by covalent docking, R-group enumeration, and relative binding free-energy calculations via free-energy perturbation (FEP), we have designed and synthesized a series of MCL analogs. These derivatives retain comparable antiproliferative potency but exhibit markedly improved physicochemical properties, including enhanced kinetic aqueous solubility and optimized lipophilicity. Microscale thermophoresis confirms C367-dependent binding, while microsecond-scale molecular dynamics simulations and pair-interaction energy analyses highlight stable complexes in which electrostatic interactions predominate, with major contributions from key residues (Lys365, Val366, and Ile368). This study establishes C367 as a druggable covalent site in the historically challenging STAT3 DBD, validates FEP-guided optimization of covalent inhibitors, and identifies compound 16 as a promising next-generation lead with a superior drug-like profile for targeting STAT3-dependent cancers. All in all, these findings provide a foundation for advancing selective STAT3 DBD inhibitors toward clinical translation.
Constitutive activation of STAT3 and dysregulation of the thioredoxin reductase 1 (TrxR1) system are deeply implicated in the pathogenesis, progression, and drug resistance of colorectal cancer (CRC). Herein, guided by a pharmacophore fusion strategy, we rationally designed and synthesized a novel series of STAT3/TrxR1...
Receptor-interacting protein kinase 1 (RIPK1) mediates cell survival, inflammation, and cell death, and its kinase-independent scaffolding function drives tumor progression and therapeutic resistance, which cannot be eliminated by conventional RIPK1 kinase inhibitors. To overcome this limitation, we adopted proteolysis...
Shun-Xin Guo, Ming-Ze Tang, Pei Yu et al.· European journal of medicina...· 0 citations
These findings position ZINC7263 as a novel, potent SMO inhibitor with a stable binding affinity, dynamic interaction stability, and promising preclinical potential for targeting Hh-driven cancers.
Arpit Sharma, Alok Shukla, S. Raut et al.· Computational biology and ch...· 0 citations
The first small-molecule GPX4 degraders that incorporate either electrophilic warheads or a minimal azide group as an E3 recruitment ligand are reported, thereby expanding the E3 ligase toolbox and offering a promising strategy for targeted cancer therapy.
Ze-Hong Lin, Kang Duan, Rui Wan et al.· Advancement of science· 0 citations
An integrated computational framework is presented that synergistically combines enhanced-sampling molecular dynamics simulations, rigorous binding free energy calculations, and quantum chemical analyses to decipher the mechanistic basis of CU-CPT22 action and establish a robust conceptual and computational framework f...
Peng Jiao, Cheng-Liang Ni, Hao Jin et al.· Journal of Molecular Graphic...· 0 citations
This work describes the design, synthesis, and biological evaluation of a series of JNK1-targeting PROTACs that recruit either CRBN or VHL E3 ligases that demonstrates excellent degradation potency and selectivity for JNK1, highlighting its potential as a valuable chemical probe for EMT-associated pathologies.
Shuhua Ren, Ye Zhang, Rui Hao et al.· Bioorganic chemistry (Print)· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.